AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30753091 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 140
Study 30753091 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal behavior modification
Number of subjects: 140
Study 30753091 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen and verbal behavior modification
Number of subjects: 140
Study 30753091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 28747245 — intervention group
Group type: EXPERIMENTAL
Intervention: General Practice Management Plan (GPMP)
Number of subjects: 6123
Study 28747245 — intervention group
Group type: COMPARATOR
Intervention: Factors associated with receiving a GPMP
Number of subjects: 6123
Study 28747245 — intervention group
Group type: COMPARATOR
Intervention: Mental Health Plan
Number of subjects: 6123
Study 25872529 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision coaching with up to three face-to-face coaching sessions with a trained nurse
Number of subjects: 300
Study 25872529 — intervention group
Group type: COMPARATOR
Intervention: Counselling as usual (control group)
Number of subjects: 300
Study 25872529 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision coaching
Number of subjects: 300
Study 24226720 — intervention group
Group type: EXPERIMENTAL
Intervention: Reformulated Ensure Plus
Number of subjects: 1771
Study 24226720 — intervention group
Group type: COMPARATOR
Intervention: Other oral nutritional supplements
Number of subjects: 1771
Study 21121958 — intervention group
Group type: EXPERIMENTAL
Intervention: PISFOP
Number of subjects: 54
Study 21121958 — intervention group
Group type: COMPARATOR
Intervention: GCFOP
Number of subjects: 54
Study 19267582 — intervention group
Group type: EXPERIMENTAL
Intervention: NovoFine 32‐gauge tip x 6 mm
Number of subjects: 119
Study 19267582 — intervention group
Group type: COMPARATOR
Intervention: NovoFine 30‐gauge tip x 8 mm
Number of subjects: 119
Study 18032219 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 g/d of B12 for participants with MMA > 271 nmol/L
Number of subjects: 93
Study 18032219 — intervention group
Group type: COMPARATOR
Intervention: 0, 25, or 100 microg/d of B12 for participants with MMA <= 271 nmol/L
Number of subjects: 93
Study 18032219 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 93
Study 15617459 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 40 mg
Number of subjects: 330
Study 15617459 — intervention group
Group type: EXPERIMENTAL
Intervention: telmisartan 80 mg
Number of subjects: 330
Study 15617459 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg
Number of subjects: 330
Study 15617459 — intervention group
Group type: COMPARATOR
Intervention: losartan 100 mg
Number of subjects: 330
Study 11765098 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions to elicit emergency care by patients at times of distress
Number of subjects: 0
Study 11765098 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in problem-solving strategies
Number of subjects: 0
Study 11765098 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive interventions including problem solving with intensive rehearsal of cognitive, social, emotional-labeling, and distress-tolerance skills
Number of subjects: 0
Study 9460431 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback‐assisted pelvic floor muscle training
Number of subjects: 0
Study 9460431 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompted voiding
Number of subjects: 0
Study 8223837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine (300 mg)
Number of subjects: 0
Study 8223837 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg)
Number of subjects: 0
Study 8223837 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (450 mg)
Number of subjects: 0
Study 8223837 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine pretreatment
Number of subjects: 0
Study 3512633 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate
Number of subjects: 103
Study 3512633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 3512633 — intervention group
Group type: EXPERIMENTAL
Intervention: Meclofenamate (open trial)
Number of subjects: 103
Study 30232857 — intervention group
Group type: EXPERIMENTAL
Intervention: Warming needle moxibustion plus diet control
Number of subjects: 60
Study 30232857 — intervention group
Group type: COMPARATOR
Intervention: Diet control
Number of subjects: 60
Study 26229089 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan 0.75 mg/day
Number of subjects: 211
Study 26229089 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan 1.25 mg/day
Number of subjects: 211
Study 26229089 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan (responders with >30% albuminuria reduction)
Number of subjects: 211
Study 26229089 — intervention group
Group type: EXPERIMENTAL
Intervention: atrasentan (non-responders)
Number of subjects: 211
Study 26229089 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 211
Study 25241957 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic method
Number of subjects: 74
Study 25241957 — intervention group
Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 74
Study 22531973 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-5 e-mail reminders
Number of subjects: 3876
Study 22531973 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 e-mail reminders
Number of subjects: 3876
Study 22531973 — intervention group
Group type: COMPARATOR
Intervention: Medium amounts of reminders (reference)
Number of subjects: 3876
Study 22531973 — intervention group
Group type: EXPERIMENTAL
Intervention: High amounts of reminders
Number of subjects: 3876
Study 22531973 — intervention group
Group type: EXPERIMENTAL
Intervention: Office workers
Number of subjects: 3876
Study 22531973 — intervention group
Group type: EXPERIMENTAL
Intervention: Field workers
Number of subjects: 3876
Study 22531973 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent reminders
Number of subjects: 3876
Study 22531973 — intervention group
Group type: EXPERIMENTAL
Intervention: September
Number of subjects: 3876
Study 19508966 — intervention group
Group type: EXPERIMENTAL
Intervention: CRx-102 (prednisolone 3 mg/day and dipyridamole 400 mg/day)
Number of subjects: 83
Study 19508966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 19508966 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite scores
Number of subjects: 83
Study 17459064 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 91
Study 17459064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention tool (structured pamphlet)
Number of subjects: 91
Study 16118673 — intervention group
Group type: COMPARATOR
Intervention: IFN-alpha monotherapy (13 patients) at 9 million units 3 times weekly for 24 weeks
Number of subjects: 27
Study 16118673 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (14 patients) with IFN-alpha at 9 million units 3 times weekly for 24 weeks plus lamivudine 100 mg/day for 1 year
Number of subjects: 27
Study 11808827 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 11
Study 11808827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 11
Study 11808827 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil and Ketamine
Number of subjects: 11
Study 11808827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10519562 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia patients
Number of subjects: 0
Study 10519562 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chiropractic care patients
Number of subjects: 0
Study 7742706 — intervention group
Group type: EXPERIMENTAL
Intervention: O2‐O3 therapy
Number of subjects: 30
Study 7742706 — intervention group
Group type: COMPARATOR
Intervention: HBO therapy
Number of subjects: 30
Study 1675576 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg (B10)
Number of subjects: 6
Study 1675576 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg (B40)
Number of subjects: 6
Study 1675576 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 80 mg (B80)
Number of subjects: 6
Study 1675576 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (A50)
Number of subjects: 6
Study 1675576 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 200 mg (A200)
Number of subjects: 6
Study 1675576 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study 6825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine
Number of subjects: 148
Study 6825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (massive single dose and then alternating daily)
Number of subjects: 148
Study 6825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar X‐radiation
Number of subjects: 148
Study 6825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphokinetic drug (Venalot‐Depot)
Number of subjects: 148
Study 6825584 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of treatments
Number of subjects: 148
Study 30100106 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.04 g hydrolyzed casein protein×kg ffm-1×2 h-1
Number of subjects: 22
Study 30100106 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 g hydrolyzed casein protein×kg ffm-1×2 h-1
Number of subjects: 22
Study 30100106 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.30 g hydrolyzed casein protein×kg ffm-1×2 h-1
Number of subjects: 22
Study 30100106 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic capacity COPD
Number of subjects: 22
Study 30100106 — intervention group
Group type: EXPERIMENTAL
Intervention: Anabolic capacity healthy
Number of subjects: 22
Study 29510651 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Therapy (GT)
Number of subjects: 65
Study 29510651 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Therapy (IT)
Number of subjects: 65
Study 29510651 — intervention group
Group type: COMPARATOR
Intervention: No Therapy (NT)
Number of subjects: 65
Study 26964798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level infrared laser (LLIL; 810 nm)
Number of subjects: 66
Study 26964798 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level red laser (LLRL; 660 nm, 200 mW, 15 s, 12 J/cm(2))
Number of subjects: 66
Study 26964798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no energy output)
Number of subjects: 66
Study 25143497 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtrapezial approach
Number of subjects: 28
Study 25143497 — intervention group
Group type: COMPARATOR
Intervention: Standard volar approach
Number of subjects: 28
Study 22379625 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist first-episode treatment plus specialist early intervention for borderline personality
Number of subjects: 16
Study 22379625 — intervention group
Group type: COMPARATOR
Intervention: Specialist first-episode treatment alone
Number of subjects: 16
Study 19967594 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (45-50% heart rate reserve)
Number of subjects: 18
Study 19967594 — intervention group
Group type: EXPERIMENTAL
Intervention: Running (80-85% heart rate reserve)
Number of subjects: 18
Study 19967594 — intervention group
Group type: COMPARATOR
Intervention: Passive control
Number of subjects: 18
Study 18727459 — intervention group
Group type: EXPERIMENTAL
Intervention: High monounsaturated fatty acid diabetes-specific supplement (49.95% calories from fats)
Number of subjects: 30
Study 18727459 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific supplement (34% calories from fats)
Number of subjects: 30
Study 15504423 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 282
Study 15504423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study 12794786 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip school led by physical therapists (T group)
Number of subjects: 145
Study 12794786 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group)
Number of subjects: 145
Study 10595601 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone administration
Number of subjects: 16
Study 8740033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboscopy (retroperitoneal laparoscopy)
Number of subjects: 20
Study 8740033 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy (transperitoneal laparoscopy)
Number of subjects: 20
Study 8740033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumboscopy
Number of subjects: 20
Study 8740033 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 20
Study 1888694 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 11
Study 1888694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7163723 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg, nightly for 2 weeks)
Number of subjects: 16
Study 7163723 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nightly for 2 weeks)
Number of subjects: 16
Study 31877311 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 sessions of anodal transcranial direct current stimulation (TDCS) over the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 123
Study 31877311 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 sessions of anodal TDCS with working memory training
Number of subjects: 123
Study 31877311 — intervention group
Group type: COMPARATOR
Intervention: 20 sessions of sham stimulation
Number of subjects: 123
Study 31877311 — intervention group
Group type: COMPARATOR
Intervention: 20 sessions of sham stimulation with working memory training
Number of subjects: 123
Study 30696255 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg tablet
Number of subjects: 0
Study 30696255 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (CXB) as internal standard
Number of subjects: 0
Study 27406397 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest compressions with music
Number of subjects: 77
Study 27406397 — intervention group
Group type: COMPARATOR
Intervention: No music (control group)
Number of subjects: 77
Study 26511848 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 262
Study 26511848 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 262
Study 26511848 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events for ASAQ
Number of subjects: 262
Study 26511848 — intervention group
Group type: COMPARATOR
Intervention: Adverse events for AL
Number of subjects: 262
Study 23398716 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D conformal treatment planning
Number of subjects: 10
Study 23398716 — intervention group
Group type: COMPARATOR
Intervention: AP-PA technique
Number of subjects: 10
Study 23398716 — intervention group
Group type: COMPARATOR
Intervention: PA technique
Number of subjects: 10
Study 20952427 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 2 µg kg⁻¹ in bupivacaine 0.2%
Number of subjects: 50
Study 20952427 — intervention group
Group type: COMPARATOR
Intervention: Morphine 30 µg kg⁻¹ in bupivacaine 0.2%
Number of subjects: 50
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness
Number of subjects: 373
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 373
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA(1c)
Number of subjects: 373
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension history
Number of subjects: 373
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 373
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported use of ED medications
Number of subjects: 373
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ED
Number of subjects: 373
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild or moderate ED
Number of subjects: 373
Study 19192106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sought medical help for ED
Number of subjects: 373
Study 17374742 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified maintenance chemotherapy (n = 89)
Number of subjects: 175
Study 17374742 — intervention group
Group type: COMPARATOR
Intervention: Observation (n = 86)
Number of subjects: 175
Study 15125746 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with radiotherapy (300 mg/m2/week)
Number of subjects: 6
Study 15125746 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 6
Study 15125746 — intervention group
Group type: COMPARATOR
Intervention: Excision followed by radiotherapy
Number of subjects: 6
Study 15125746 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine with radiotherapy
Number of subjects: 6
Study 12397466 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadramet (samarium‐153 EDTMP) at an average dose of 740 MBq in tracer studies and up to 50 GBq in therapy infusions.
Number of subjects: 42
Study 12397466 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadramet (samarium‐153 EDTMP) at an average dose of 740 MBq in tracer studies.
Number of subjects: 42
Study 9817174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravity-assisted positioning head downward tip (Episode A)
Number of subjects: 21
Study 9817174 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse order positioning (Episode B)
Number of subjects: 21
Study 9817174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting position during physiotherapy
Number of subjects: 21
Study 7661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (2.5 g of colestipol plus 2.5 g of psyllium)
Number of subjects: 121
Study 7661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol alone (5 g)
Number of subjects: 121
Study 7661492 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium alone (5 g)
Number of subjects: 121
Study 7661492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5 g cellulose)
Number of subjects: 121
Study 2034085 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy using large field radiotherapy (total irradiation of 20 Gy, daily fractionation of 4 Gy) and induced hyperglycemia (22‐23 mmol/l)
Number of subjects: 0
Study 2034085 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hyperglycemia before radiotherapy sessions
Number of subjects: 0
Study 2034085 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced hyperglycemia after discontinuation of radiotherapy sessions
Number of subjects: 0
Study 7034431 — intervention group
Group type: EXPERIMENTAL
Intervention: metronidazole-fosfomycin
Number of subjects: 58
Study 7034431 — intervention group
Group type: COMPARATOR
Intervention: metronidazole-cephalothin
Number of subjects: 58
Study 31658148 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged dual antiplatelet therapy (DAPT) (>12 months)
Number of subjects: 5
Study 30955096 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision-assisted orthodontic treatment
Number of subjects: 24
Study 30955096 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthodontic treatment
Number of subjects: 24
Study 28644196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol 200 μg once daily
Number of subjects: 0
Study 28644196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol 400 μg once daily
Number of subjects: 0
Study 28644196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol 600 μg once daily
Number of subjects: 0
Study 28644196 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol 200 mg twice daily
Number of subjects: 0
Study 28644196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28644196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol (all doses)
Number of subjects: 0
Study 28644196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol (target doses)
Number of subjects: 0
Study 28644196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cebranopadol (maintenance phase)
Number of subjects: 0
Study 23975362 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary program, n=108
Number of subjects: 203
Study 23975362 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program, n=47
Number of subjects: 203
Study 23975362 — intervention group
Group type: COMPARATOR
Intervention: Usual care, n=48
Number of subjects: 203
Study 25775881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration iodinated contrast medium (Iodixanol, 270 mg I/ml) with low tube voltage (80 kV)
Number of subjects: 60
Study 25775881 — intervention group
Group type: COMPARATOR
Intervention: High-concentration iodinated contrast medium (Iodixanol, 320 mg I/ml) with standard tube voltage (120 kV)
Number of subjects: 60
Study 25775881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration iodinated contrast medium (Iodixanol, 270 mg I/ml)
Number of subjects: 60
Study 25775881 — intervention group
Group type: COMPARATOR
Intervention: High-concentration iodinated contrast medium (Iodixanol, 320 mg I/ml)
Number of subjects: 60
Study 23069363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based Green Prescription
Number of subjects: 330
Study 23069363 — intervention group
Group type: COMPARATOR
Intervention: Time-based Green Prescription
Number of subjects: 330
Study 19930003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation
Number of subjects: 311
Study 17323788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium dihydrate (256 mg sodium salt, equivalent to 200 mg ibuprofen)
Number of subjects: 396
Study 17323788 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen acid (200 mg ibuprofen)
Number of subjects: 396
Study 15143880 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy with biweekly administration of 1000 mg/m2 gemcitabine
Number of subjects: 21
Study 15143880 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 21
Study 11197282 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 318
Study 11197282 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 318
Study 11197282 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 10 mg
Number of subjects: 318